As of 23 Sept 2026, Syncom Formulations (India) Ltd share price is ₹20.40. The stock opened at ₹20.40 and had closed at ₹19.80 the previous day. Over the last 52 weeks, the stock has recorded a low of ₹10.21 and a high of ₹22.52. In terms of performance, Syncom Formulations (India) Ltd share price has increased by 79.26% over the past six months and has increased by 18.67% over the last year.
SYNCOMF Stock Price Chart
Syncom Formulations (India) Ltd Overview
About SYNCOMF
Syncom Formulations (India) is a renowned name in the Indian Pharmaceutical Industry represents synergistic combination of commitment and consistency. Currently Syncom manufactures and markets more than 200 pharmaceutical formulations products in various dosage forms like Tablets, Capsules, Liquids Orals, Liquid Vials and Ampoule Injections & Dry Vial injections, Dry Syrups, Ointments and Inhalers.
Syncom Formulations (India) Ltd Historical Performance
Syncom Formulations (India) Ltd Fundamentals
Syncom Formulations (India) Ltd Financials
| Indicator | Mar 26 | Mar 25 | Mar 24 | Mar 23 | Mar 22 |
|---|---|---|---|---|---|
| Revenue | 517.54 | 480.04 | 271.46 | 239.25 | 231.65 |
| EBITDA | 108.16 | 70.70 | 40.93 | 34.24 | 32.06 |
| Net Profit | 76.01 | 48.87 | 23.62 | 20.07 | 19.79 |
| EPS | 0.81 | 0.52 | 0.32 | 0.20 | 0.26 |
Syncom Formulations (India) Ltd Technical Analysis
| Indicator | Value |
|---|---|
| Support 1 (S1) | 19.45 |
| Resistance 1 (R1) | 20.32 |
| Pivot Point | 19.98 |
Syncom Formulations (India) Ltd Dividend History
| Ex Date | Dividends Date | Record Date | Dividend Type | Dividend Details |
|---|---|---|---|---|
| 23-Sep-2026 | 11-Aug-2026 | 23-Sep-2026 | Final | ₹0.10 |
| 09-Sep-2022 | 13-Aug-2022 | 13-Sep-2022 | Final | ₹0.03 |
SYNCOMF Key Leadership Details
Last Updated: Mar 2025
| Name | Position |
|---|---|
| Ruchi Jindal | Non Executive Independent Director |
| Ritesh Kumar Lunkad | Non Executive Independent Director |
| Ankit Jain | Non Executive Independent Director |
Syncom Formulations (India) Ltd Peer Comparison
| Company | Price | M.Cap (Cr) | P/E (TTM) | ROE (TTM) |
|---|---|---|---|---|
| Sun Pharmaceutical Industries LtdSUNPHARMA | ₹1,846.40-1.20% | ₹4,19,727.66 | 38.32 | 13.74% |
| Divis Laboratories LtdDIVISLAB | ₹9,352.00-0.62% | ₹1,67,235.91 | 67.46 | 15.32% |
| Torrent Pharmaceuticals LtdTORNTPHARM | ₹4,935.00-0.70% | ₹1,46,951.32 | 64.68 | 25.49% |
Disclaimer
The information provided on this page is for informational purposes only and should not be construed as investment advice, recommendation, or solicitation to buy or sell any securities or financial pr...
Frequently Asked Questions
- The share price of Syncom Formulations (India) Ltd today is ₹20.40 on NSE and ₹20.40 on BSE.
- The 52-week high of Syncom Formulations (India) Ltd is ₹22.52, while the 52-week low is ₹10.21.
- The current market capitalisation of Syncom Formulations (India) Ltd is approximately ₹1,918 crore.
- The P/E (Price-to-Earnings) ratio of Syncom Formulations (India) Ltd is 16.60. The ratio may vary with changes in the share price and earnings.
- The P/B (Price-to-Book) ratio of Syncom Formulations (India) Ltd is 3.01. It compares the company’s market value with its book value and can provide an indication of how the market values the company relative to its net assets.
- To buy Syncom Formulations (India) Ltd shares, you first need to open a demat account before you can place an order. Here's the process:
• Open a demat account online using your PAN, Aadhaar and bank details.
• Add funds to your trading account via UPI or net banking.
• Search for SYNCOMF on TradeMobi or the Anand Rathi web platform.
• Place your order
• Track your holdings in the portfolio section. - Over the past 3 years, Syncom Formulations (India) Ltd has delivered a return of approximately 136.38%. This return is based on the change in the share price over the specified period and may differ depending on the measurement date. Past performance does not guarantee future returns.
- The shareholding pattern of Syncom Formulations (India) Ltd comprises different categories of shareholders. As of Jun 2026, the shareholding is approximately 50.57% promoters, 0.35% FIIs, 0.00% DIIs, and 44.90% public shareholders.

